LLY - Eli Lilly and Company - Stock & Dividends

Exchange: XETRA Stock Exchange • Country: United States • Currency: EUR • Type: Common Stock • ISIN: US5324571083

Diabetes, Oncology, Autoimmune, Pain, Cardiovascular

Eli Lilly and Company is a global leader in pharmaceuticals, dedicated to discovering, developing, and marketing life-changing medicines worldwide.

The company has a strong presence in the diabetes market, offering a range of products including Basaglar, Humalog, and Humulin, which help millions of people manage their diabetes. Additionally, they provide innovative treatments like Jardiance, Mounjaro, and Trulicity for type 2 diabetes, as well as Zepbound for obesity.

In the field of oncology, Eli Lilly and Company offers a portfolio of products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, which are designed to combat various types of cancer.

Furthermore, the company has a diverse range of products for other therapeutic areas, including Olumiant for rheumatoid arthritis and atopic dermatitis, Taltz for plaque psoriasis and psoriatic arthritis, Omvoh for ulcerative colitis, Cymbalta for depressive disorders and chronic pain, Ebglyss for severe atopic dermatitis, and Emgality for migraine prevention.

Moreover, Eli Lilly and Company offers Cialis for erectile dysfunction and benign prostatic hyperplasia, as well as Forteo for osteoporosis. The company has established collaborations with several other pharmaceutical companies, including Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, F. Hoffmann-La Roche, Genentech, Biologics, AbCellera Biologics, and Chugai Pharmaceutical.

Founded in 1876, Eli Lilly and Company is headquartered in Indianapolis, Indiana, and has a long history of innovation and commitment to improving human health. You can learn more about the company and its products at https://www.lilly.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for LLY - Eli Lilly and Company  - Stock & Dividends

LLY Stock Overview

Market Cap in USD 844,852m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception

LLY Stock Ratings

Growth 5y 95.4
Fundamental 44.2
Dividend 49.51
Rel. Performance vs Sector 2.79
Analysts -
Fair Price Momentum 1095.82 EUR
Fair Price DCF -

LLY Dividends

Dividend Yield 12m 0.57%
Yield on Cost 5y 5.10%
Dividends CAGR 5y 11.87%
Payout Consistency 75.6%

LLY Growth Ratios

Growth 12m 92.84%
Growth Correlation 12m 80%
Growth Correlation 3m 85%
CAGR 5y 54.54%
CAGR/Mean DD 5y 9.25
Sharpe Ratio 12m 2.63
Alpha vs SP500 12m 79.35
Beta vs SP500 5y weekly 0.44
ValueRay RSI 3.59
Volatility GJR Garch 1y 48.67%
Price / SMA 50 -1.88%
Price / SMA 200 17.93%
Current Volume 7.5k
Average Volume 20d 3.9k

External Links for LLY Stock

Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of LLY stocks?
As of July 19, 2024, the stock is trading at EUR 781.20 with a total of 7,514 shares traded.
Over the past week, the price has changed by -8.54%, over one month by -6.32%, over three months by +11.39% and over the past year by +89.96%.
What are the forecast for LLY stock price target?
According to ValueRays Forecast Model, LLY Eli Lilly and Company will be worth about 1201.5 in July 2025. The stock is currently trading at 781.20. This means that the stock has a potential upside of +53.8%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 1201.5 53.8

A Look into Eli Lilly and Company: From Foundation to Market Leader

History of Eli Lilly and Company

Eli Lilly and Company, often recognized simply as Lilly, traces its roots back to 1876. It was founded by Colonel Eli Lilly, a pharmacist and veteran of the American Civil War, in Indianapolis, Indiana. The company's formation was driven by Lilly's commitment to creating high-quality, scientifically backed medications following his dissatisfaction with the unreliable and often ineffective medicines of his time.

Core Business

At its core, Eli Lilly and Company is dedicated to creating medicines that help improve people's lives around the globe. Over the years, Lilly has made significant strides in a variety of therapeutic areas including diabetes, oncology, neurodegeneration, and immunology. Their focus on innovative research and development has led to the creation of numerous drugs that have had a profound impact on patient care.

Side Businesses and Diversification

In addition to its pharmaceutical ventures, Eli Lilly and Company has also explored various side businesses over the years. This includes their involvement in animal health through their subsidiary Elanco, which was spun off as an independent company in 2018. Lilly has been involved in various other sectors as well, including agricultural chemicals and beauty products in the past, showcasing their interest in diversifying their business portfolio.

Current Market Status

Today, Eli Lilly and Company stands as one of the leading pharmaceutical companies worldwide. With a strong emphasis on innovation and a robust pipeline of drugs in various stages of development, Lilly continues to strive toward addressing some of the most challenging health issues facing the world. As of 2023, the company remains a significant player in the pharmaceutical industry, with a noticeable presence in global markets and a commitment to improving health outcomes for patients around the world.